DrugPatentWatch Database Preview
VELCADE Drug Profile
When do Velcade patents expire, and when can generic versions of Velcade launch?
Velcade is a drug marketed by Millennium Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-four patent family members in twelve countries.
The generic ingredient in VELCADE is bortezomib. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
Summary for VELCADE
| International Patents: | 24 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 98 |
| Clinical Trials: | 546 |
| Patent Applications: | 76 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VELCADE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VELCADE |
| DailyMed Link: | VELCADE at DailyMed |
Recent Clinical Trials for VELCADE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Takeda | Phase 2 |
| Mayo Clinic | Phase 1 |
| Leaf Vertical Inc. | Phase 1/Phase 2 |
Recent Litigation for VELCADE
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Millennium Pharmaceuticals, Inc. v. Hetero Labs Limited | 2018-10-22 |
| Millennium Pharmaceuticals, Inc. v. Qilu Pharmaceutical Co., Ltd. | 2017-12-20 |
| Millennium Pharmaceuticals Inc. v. Hospira, Inc. | 2016-10-26 |
Pharmacology for VELCADE
| Drug Class | Proteasome Inhibitor |
| Mechanism of Action | Proteasome Inhibitors |
Synonyms for VELCADE
| ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid |
| ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid |
| (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR |
| (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid |
| (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid |
| [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid |
| [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid |
| [(1R)-3-METHYL-1-[[(2S)-1-OXO-3-PHENYL-2-[(PYRAZINYLCARBONYL)AMINO]PROPYL]AMINO]BUTYL]-BORONIC ACID |
| [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid |
| [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid |
| 179324-69-7 |
| 197730-97-5 |
| 324B697 |
| 3mg0 |
| 69G8BD63PP |
| AB0017579 |
| AB01273951_03 |
| AB01273951-01 |
| AB01273951-02 |
| AB2000734 |
| ABP000234 |
| AC1L8TUW |
| AKOS015909706 |
| AM81235 |
| ANW-61718 |
| AOB6368 |
| API0001750 |
| AS-15721 |
| AX8106087 |
| BC201423 |
| BDBM50069989 |
| Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)- |
| Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))- |
| Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- |
| Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]- |
| Bortezomib |
| Bortezomib (JAN/USAN/INN) |
| Bortezomib (PS-341) |
| Bortezomib (Velcade MG-341 PS-341) |
| Bortezomib (Velcade) |
| Bortezomib [USAN:INN:BAN] |
| Bortezomib,Velcade |
| Bortezomib/Velcade, MG-341, PS-341 |
| BRD-K88510285-001-02-0 |
| C19H25BN4O4 |
| CAS-179324-69-7 |
| CB0261 |
| cc-75 |
| CHEBI:52717 |
| CHEMBL325041 |
| CS-1039 |
| CTK8B8979 |
| D03150 |
| DB00188 |
| DPBA |
| DSSTox_CID_20980 |
| DSSTox_GSID_40980 |
| DSSTox_RID_79609 |
| DTXSID3040980 |
| FT-0082488 |
| FT-0602235 |
| GTPL6391 |
| GXJABQQUPOEUTA-RDJZCZTQSA-N |
| HSDB 7666 |
| HY-10227 |
| I14-3268 |
| KB-48452 |
| KS-00000761 |
| LDP 341 |
| LDP-341 |
| LPD 341 |
| LPD-341 |
| MFCD09056737 |
| MG 341 |
| MG-341 |
| MG-341; PS-341 |
| MLN-341 |
| MLS004774142 |
| MolPort-003-845-298 |
| N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide |
| N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide |
| N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide |
| N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide |
| N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE |
| NCGC00168751-01 |
| NCGC00181022-01 |
| NCGC00242506-01 |
| NCGC00242506-02 |
| NCGC00242506-07 |
| NCI60_029010 |
| NSC 681239 |
| NSC-681239 |
| NSC681239 |
| PB14673 |
| PROSCRIPT BORONIC ACID |
| Ps 341 |
| PS 341 (pharmaceutical) |
| PS 341; Velcade |
| PS-341 |
| PubChem17777 |
| Pyz-Phe-boroLeu |
| Q-4365 |
| Q425 |
| RL02288 |
| RT-000308 |
| S1013 |
| SC-23571 |
| SCHEMBL192129 |
| SMR003500787 |
| SR-01000939863 |
| SR-01000939863-2 |
| ST2406732 |
| SW208077-3 |
| Tox21_112630 |
| Tox21_112672 |
| Tox21_112672_1 |
| UNII-69G8BD63PP |
| Velcade (Millenium) |
| Velcade (TN) |
| Velcade, MG-341, PS-341,179324-69-7 |
| ZINC169746649 |
US Patents and Regulatory Information for VELCADE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VELCADE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| Millennium Pharms | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | See Pricing | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VELCADE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 3.5 mg/vial | ➤ Subscribe | See Pricing |
International Patents for VELCADE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 1355910 | See Pricing |
| European Patent Office | 3078667 | See Pricing |
| European Patent Office | 1360189 | See Pricing |
| European Patent Office | 1355910 | See Pricing |
| Japan | 2004517931 | See Pricing |
| Cyprus | 1117484 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VELCADE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0788360 | 04C0014 | France | See Pricing | PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426 |
| 0788360 | SPC/GB04/021 | United Kingdom | See Pricing | PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
